Durvalumab plus S-488210/S-488211 vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in patients with Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer.
@myESMO #ESMOAsia24
#ESMOAsia24